Status:

COMPLETED

Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy

Lead Sponsor:

University Medical Center Groningen

Conditions:

Melanoma

Non-small Cell Lung Cancer (NSCLC)

Eligibility:

All Genders

18+ years

Brief Summary

Background of the study: Immune checkpoint inhibitors (ICIs) are widely used as treatment for multiple cancer types and the number of patients with longterm disease control after ICIs is increasing. ...

Detailed Description

In this cross-sectional study, patients with melanoma, NSCLC or urogenital cancer ≥ 2 years following ICI therapy and their caregivers will be included. The investigators will include patients who hav...

Eligibility Criteria

Inclusion

  • 1\. Patients with melanoma, NSCLC or urogenital cancers \> 2 years since treatment with at least one cycle of immune checkpoint inhibitor (CTLA-4 inhibitor, PD-(L)1 inhibitor, or both) within the Department of Medical Oncology or Pulmonary Oncology of the UMCG.
  • 2\. Age \>18 years at time of immune checkpoint inhibitor treatment
  • 3\. Understand or abide to the study procedures
  • 4\. Have given informed consent
  • A caregiver must meet all of the following criteria:
  • 1\. Age \>18 years
  • 2\. Understand or abide to the study

Exclusion

  • 1\. As previous or subsequent therapies, only surgery and palliative radiotherapy is allowed (excluding radiotherapy in the head-neck and brain region)
  • 2\. Previous treatment in the past ten years for malignancy other than melanoma (excluding non-melanoma skin cancer, cervical intra-epithelial neoplasia (CIN) or carcinoma in situ of breast) (for patients: other than current malignancy)
  • 3\. History of ear-nose-throat disease or auto-immune disorder affecting taste, smell, mouth mucosa, or saliva production (for patients: before start ICI)

Key Trial Info

Start Date :

October 26 2023

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

February 11 2025

Estimated Enrollment :

101 Patients enrolled

Trial Details

Trial ID

NCT06495008

Start Date

October 26 2023

End Date

February 11 2025

Last Update

March 5 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Medical Center Groningen

Groningen, Netherlands, 9713 GZ

Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy | DecenTrialz